FAKE DRUGS - BOOM PUMMELS PHARMA INDUSTRY
BioSpectrum Asia|BioSpectrum Asia May 2021
Fake pharmaceuticals are continuing to flood into clinics and hospitals across Asia despite monitored regulations in China and India, when suppliers crossing the border to less-regulated countries. Counterfeiters are moving across certain less regulated locations in Southeast Asia to sustain the trade. Pharmaceutical industry is committed and thriving to sustain and secure the legitimate supply chain. Given the complexity of the supply chain, this is an essential, but laborious effort that requires an efficient, multi-faceted strategy. A holistic approach comprising the use of concealed and unconcealed anti-counterfeiting features, a well-regulated, secure supply chain and appropriate laws and penalties to deter and punish counterfeiters is necessary to provide maximum patient protection.
Hithaishi C Bhaskar
FAKE DRUGS - BOOM PUMMELS PHARMA INDUSTRY

As the COVID-19 pandemic continues to affect the world and with the global rush in the development and distribution of vaccines, criminal groups and unscrupulous enterprising people have also been active in counterfeiting COVID-19-related health products. The Philippines through the Philippine Center on Transnational Crime, INTERPOL National Central Bureau, Office of the President of The Philippines has received reports that South African authorities have seized hundreds of fake COVID-19 vaccines and Some 400 ampoules containing the fake vaccine were found at a warehouse in Germiston, Gauteng. Further investigation by the INTERPOL revealed the presence of organized crime networks targeting COVID-19 vaccines, both physically and online. Concerned pharmaceutical companies assisted in the identification of fake vials. Criminals have been put behind bars and investigations are continuing.

According to a FDA Advisory No. 20210664 by The Philippines authorities on Public Health Warning on Fake COVID-19 Vaccines, it noted that in February 2021, the World Health Organization (WHO) reported that a falsified COVID-19 vaccine in Mexico identified as “BNT162b2”, manufactured by Pfizer- BioNTech with lot number 783201. The falsified product was supplied and administered to patients outside authorized vaccination programs. The genuine manufacturer of COVID-19 Vaccine BNT162b2 confirmed they did not manufacture the product. Laboratory analysis of the contents of the falsified products is still pending as of today. Falsified COVID-19 vaccines pose a serious risk to global public health and place an additional burden on vulnerable populations and health systems.

This story is from the {{IssueName}} edition of {{MagazineName}}.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the {{IssueName}} edition of {{MagazineName}}.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM BIOSPECTRUM ASIAView all
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
BioSpectrum Asia

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
BioSpectrum Asia

Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers

Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
BioSpectrum Asia

Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine

Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
BioSpectrum Asia

Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis

US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singapore designs novel gene therapy offering hope for epilepsy patients
BioSpectrum Asia

Singapore designs novel gene therapy offering hope for epilepsy patients

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Spider venom heart drug moves to clinical trials in Australia
BioSpectrum Asia

Spider venom heart drug moves to clinical trials in Australia

A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).

time-read
1 min  |
BioSpectrum Asia Nov 2024
India develops portable ultrasound scanner for sports injury diagnosis
BioSpectrum Asia

India develops portable ultrasound scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Integris appoints medtech veteran Probir Das as new CEO
BioSpectrum Asia

Integris appoints medtech veteran Probir Das as new CEO

Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Clarity Pharma promotes Michelle Parker to CEO
BioSpectrum Asia

Clarity Pharma promotes Michelle Parker to CEO

Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
BioSpectrum Asia

Dr Makoto Sugita steps in as President of Nxera Pharma Japan

Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.

time-read
1 min  |
BioSpectrum Asia Nov 2024